Michael J. Hennessy Associates, Inc. combines the power of heavyweight publishing capabilities with intimate, dedicated attention to the needs of our clients and audience. Whether or not you know our name, the chances are pretty good you’ve seen one or more of our brands. We fuse the key benefits of a major publisher and a full-service communications and media provider with the attention to detail and adaptability of a truly entrepreneurial enterprise.


    Through expert reporting, conference coverage, and our Peer Exchange® and Insights series, we offer medical research and breaking news to general physicians and specialty oncologists. Recently, we extended our services into the fields of dentistry and animal health.


    We are a full-service pharmacy media resource and a leader in the industry. Our portfolio includes digital, mobile, print, live events, and custom education offerings to deliver practical information and timely news that covers all facets of pharmacy, including the specialty space.


    Our leading peer-reviewed journals publish research that is critical to clinical and policy decision makers as they work to promote the efficient delivery of high-quality care. We collect stakeholder views from payers, providers, policymakers, and pharmaceutical leaders.


    Our patient portals inform and inspire patients, survivors, and caregivers through their health journey. We offer guidance for patients with cancer and the rare disease community, and support others through disease-specific information to help them understand their conditions.


    We partner with leading cancer centers, schools of nursing, oncology networks, and societies across the country to bring physicians, pharmacists, and patients the latest in research and practice improvement. Our exclusive partnerships offer unmatched insights.


Rare Disease Report® Highlights Dr. Freyer on Hearing Loss Caused by Chemotherapy Agent During a Recent Interview

  • 2017-05-24 13:48:35

During the American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting, Rare Disease Report® the digital component of Rare Disease Communications®, conducted an interview featuring David Freyer, DO, MS, Children’s Hospital of Los Angeles and professor of pediatrics at Keck School of Medicine, University of Southern California, to better understand the effects of sodium thiosulfate in children and adults treated with cisplatin during chemotherapy.

Physicians' Education Resource® to Launch New Microsite on the Value of Continuing Medical Education in Oncology

  • 2017-05-22 16:32:31

Physicians’ Education Resource® (PER®), your top-notch online destination for oncology and hematology continuing medical education (CME), is excited to launch a website section titled, “The Value of Continuing Medical Education,” announced Phil Talamo, president. Accessible through the existing PER® Website, the upcoming section consolidates the importance of continuing medical education with video interviews from key opinion leaders.

FDA's Pazdur Outlines How Oncology Center of Excellence Will Promote Collaboration in AJMC®'s Evidence-Based Oncology™

  • 2017-05-18 14:22:29

During his 18 years at FDA, Richard Pazdur, MD, has worked to balance the needs of patients anxious for new cancer cures with the agency’s standards that protect them from harm. In January, Pazdur took on a new role—director of the new Oncology Center of Excellence (OCE), which was borne of the National Cancer Moonshot’s call for greater collaboration among those charged with speeding the arrival of new cancer-fighting products.

OncLive® To Host State of the Science Summit™ : Diagnosis, Management and Treatment of Multiple Myeloma

  • 2017-05-17 15:31:47

OncLive®, a leading digital provider of resources and information to oncology professionals, will present the State of the Science Summit™: Diagnosis, Management and Treatment of Multiple Myeloma, hosted at The Westin Charlotte, in Charlotte, North Carolina, on June 8, from 5:30-9 p.m. The summit, which follows the nation’s largest oncology meeting, will be chaired by Saad Z. Usmani, M.D., a hematologist and director of the Plasma Cell Disorder program and the director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute /Carolinas Healthcare System. The program will also have presentations by multiple myeloma specialists and hematology experts from Levine Cancer Institute.


2 Clarke Dr #100
Cranbury Township, NJ 08512

Phone: (609) 716-7777

Fax: (609) 716-9038